Heart failure & cardiomyopathies
Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Left Ventricular Assist Devices
Main finding · Heart transplantationResult — go to the resultAdjusted odds ratio 2.514 95% CI 1.720–3.673Authors' conclusion
GLP1-RA therapy in patients with advanced HF and LVADs is potentially associated with improved heart transplantation rates while decreasing hospitalization and acute HF event rates.
Study context
- Population
- Adult LVAD recipients (≥18 years)after propensity score matching (PSM)
- Participants
- 1,036 recipients
- Exposure
- GLP1-RA users vs non-users
- GLP1-RAn = 518
- Non-GLP1-RAn = 518reference
- Outcome
- Heart transplantation
Methodological detailspropensity-score matched (1:1), TriNetX database, 98 healthcare organizations, Mean follow-up 311.6 ± 98.4 days (GLP1-RA) and 304.0 ± 111.5 days (non-GLP1-RA)
- Propensity-score matched (1:1)
- TriNetX database, 98 healthcare organizations
- Mean follow-up 311.6 ± 98.4 days (GLP1-RA) and 304.0 ± 111.5 days (non-GLP1-RA)
Main finding
As reported in the abstract
Adjusted odds ratio
2.514
95% CI 1.720–3.673
Events by group
GLP1-RAvs Non-GLP1-RA
aOR 2.514 (95% CI 1.720–3.673)
Observational data: associations, not effects.
Further findings
| Outcome | GLP1-RA | Non-GLP1-RA | aOR (95% CI) | |
|---|---|---|---|---|
| Acute HF eventsCI as printed | 55.6% | 68.9% | 0.565 (0.438–728) | |
| All-cause hospitalizations | 62.5% | 75.3% | 0.548 (0.420–0.716) | |
| All-cause mortalityNo difference | 6.2% | — not stated in the abstract | 0.709 (0.442–1.138) | |
| StrokeNo difference | 8.1% | 11.2% | 0.700 (0.461–1.062) | |
| Cardiac arrestNo difference | 3.5% | 3.3% | 1.061 (0.541–2.082) | |
| 0.050.21520Adjusted odds ratio (log scale) |
— not stated in the abstract
Original publication
Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Left Ventricular Assist Devices. ESC Heart Fail. Published 13 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →